Ligand Pharma (LGND) Tops Q3 EPS by 54c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $285.60 --0%
Revenue Growth %: -32.2%
Financial Fact:
Net income (loss):: 1.05M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -32.2%
Financial Fact:
Net income (loss):: 1.05M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q3 EPS of $1.58, $0.54 better than the analyst estimate of $1.04. Revenue for the quarter came in at $64.8 million versus the consensus estimate of $55.65 million.
GUIDANCE:
Ligand Pharma sees FY2021 EPS of $5.80-$6.05, versus the consensus of $5.93. Ligand Pharma sees FY2021 revenue of $265-275 million, versus the consensus of $270 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Downgrades Phreesia Inc. (PHR) to Market Perform
- Marathon Petroleum (MPC) PT Raised to $450 at UBS
- Roth/MKM Downgrades eGain Corporation (EGAN) to Neutral
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
